Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIODESIX INCBDSX · Entity 6053 | Director | January 02, 2026 | January 06, 2026 |
| Dimension Therapeutics, Inc.DMTX · Entity 172012 | Chief Financial Officer | February 01, 2017 | February 03, 2017 |
| Disc Medicine, Inc.IRON · Entity 2273 | Chief Financial Officer | April 13, 2026 | April 15, 2026 |
| MERRIMACK PHARMACEUTICALS INCMACK · Entity 95770 | Chief Financial Officer | December 11, 2018 | December 13, 2018 |
| Replimune Group, Inc.REPL · Entity 4707 | Chief Financial Officer | May 16, 2023 | May 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIODESIX INC
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,164 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 8,164 · Balance 8,164 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2036-01-01 | Direct | 6,354 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 6,354 · Balance 6,354 F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").
F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.
Dimension Therapeutics, Inc.
Report date February 01, 2017 · Filed February 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2027-01-31 | Direct | 60,000 |
Reported balance
After 2017-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-01 · Grant · Acquired 60,000 · Balance 60,000 F1: This stock option vests in forty-eight (48) equal monthly installments beginning on January 18, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option vests in forty-eight (48) equal monthly installments beginning on January 18, 2017.
Disc Medicine, Inc.
Report date April 13, 2026 · Filed April 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,333 |
Ending reported balance
After 2026-04-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-13 · Sale · Disposed 400 · Balance 70,590 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025. Row 2 · 2026-04-14 · Sale · Disposed 6,257 · Balance 64,333 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.07 to $69.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.07 to $69.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
MERRIMACK PHARMACEUTICALS INC
Report date December 11, 2018 · Filed December 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.15 · Expires 2028-12-10 | Direct | 45,000 |
Reported balance
After 2018-12-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-11 · Grant · Acquired 45,000 · Balance 45,000 F1: This option vests as to 1/12th of the total number of shares granted on 3/11/19 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 12/11/21. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests as to 1/12th of the total number of shares granted on 3/11/19 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 12/11/21.
Replimune Group, Inc.
Report date May 16, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 128,748 |
Reported balance
After 2023-05-16 transaction · row 1
1 source rowRow 1 · 2023-05-16 · Sale · Disposed 11,351 · Balance 128,748 F1: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.23. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person.
F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.23. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2026 Filed Apr 15, 2026 20:53 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 6,257 | $69.24 | $433,234.05 |
DisclosureSEC source: 0001193125-26-157187 · ownership.xml · nonDerivative · entry 2 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,333 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.07 to $69.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| April 13, 2026 Filed Apr 15, 2026 20:53 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 400 | $69.00 | $27,600.00 |
DisclosureSEC source: 0001193125-26-157187 · ownership.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,590 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:49 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 353 | $69.06 | $24,377.09 |
DisclosureSEC source: 0001193125-26-083027 · ownership.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,990 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.00 to $69.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:42 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 3,684 | $65.89 | $242,734.71 |
DisclosureSEC source: 0001193125-26-059760 · ownership.xml · nonDerivative · entry 3 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,343 F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.51 to $66.38, inclusive. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:42 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 3,397 | $65.01 | $220,837.95 |
DisclosureSEC source: 0001193125-26-059760 · ownership.xml · nonDerivative · entry 2 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,027 F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.47 to $65.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:42 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 4,075 | $62.86 | $256,154.50 |
DisclosureSEC source: 0001193125-26-059760 · ownership.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,424 F1 · kind: This transaction represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I. This sale is a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 00:26 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 25,500 | $0.00 Strike: $74.75 | $0.00 |
DisclosureSEC source: 0001193125-26-047163 · ownership.xml · derivative · entry 2 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 25,500 shares Expires 2036-02-09 F2 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 00:26 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-047163 · ownership.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,499 F1 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:27 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to Buy) · Derivative | 6,354 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0000905148-26-000074 · form4.xml · derivative · entry 2 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,354 Underlying: Common Stock · 6,354 shares Expires 2036-01-01 F4 · derivative.exercise_date: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:27 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 8,164 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000074 · form4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,164 Underlying: Common Stock · 8,164 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2 · derivative.exercise_date: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:51 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 2,031 | $59.00 | $119,829.00 |
DisclosureSEC source: 0000950170-25-096967 · ownership.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,499 F1 · kind: The transaction reported by the Reporting Person was effected pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2025. Read SEC document |
| July 10, 2025 Filed Jul 15, 2025 01:36 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 2,000 | $57.50 | $115,000.00 |
DisclosureSEC source: 0000950170-25-095684 · ownership.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,530 F1 · kind: The transaction reported by the Reporting Person was effected pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2025. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 21:18 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 2,000 | $52.26 | $104,518.80 |
DisclosureSEC source: 0000950170-25-087963 · ownership.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,530 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.79 to $52.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:14 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to Buy) · Derivative | 42,010 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0000905148-25-001892 · form4.xml · derivative · entry 2 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,010 Underlying: Common Stock · 42,010 shares Expires 2035-05-19 F4 · derivative.exercise_date: This option will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:14 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 92,429 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001892 · form4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,429 Underlying: Common Stock · 92,429 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2 · derivative.exercise_date: These RSUs will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:26 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 26,368 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001049 · form4.xml · derivative · entry 2 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: These fully vested RSUs settled on April 1, 2025, and had no expiration date. F2 · derivative.expiration_date: These fully vested RSUs settled on April 1, 2025, and had no expiration date. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:26 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 26,368 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-25-001049 · form4.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 00:29 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 3,136 | $54.58 | $171,162.88 |
DisclosureSEC source: 0000950170-25-024472 · ownership.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,530 F1 · kind: This transaction represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units granted on February 7, 2024 and previously reported in Table I. This sale is a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 23:38 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $54.71 | $0.00 |
DisclosureSEC source: 0000950170-25-019092 · ownership.xml · derivative · entry 2 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2035-02-09 F2 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2025, subject to the Reporting Person's continuted service on each such vesting date. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 23:38 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-019092 · ownership.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,666 F1 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 21, 2024 Filed May 23, 2024 23:13 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to Buy) · Derivative | 37,050 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0000905148-24-001607 · form4.xml · derivative · entry 2 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,050 Underlying: Common Stock · 37,050 shares Expires 2034-05-20 F4 · derivative.exercise_date: This option will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, this option will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document |
| May 21, 2024 Filed May 23, 2024 23:13 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 60,766 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001607 · form4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,766 Underlying: Common Stock · 60,766 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document |
| February 07, 2024 Filed Feb 16, 2024 01:37 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $65.25 | $0.00 |
DisclosureSEC source: 0000950170-24-016133 · ownership.xml · derivative · entry 2 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2034-02-06 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on February 7, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 07, 2024 Filed Feb 16, 2024 01:37 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantCommon Stock | 36,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016133 · ownership.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,666 Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:14 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 105,389 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000039 · form4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,811 Underlying: Common Stock · 105,389 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:28 UTC | BIODESIX INC BDSX · Entity 6053 | GrantCommon Stock | 61,728 | $1.62 | $99,999.36 |
DisclosureSEC source: 0000905148-23-000619 · form4.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,772 Read SEC document |
| May 23, 2023 Filed May 25, 2023 22:22 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 40,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-026721 · form4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,422 Underlying: Common Stock · 40,422 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F4 · derivative.underlying_shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. F4 · balance_after: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document |
| May 16, 2023 Filed May 19, 2023 00:32 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,351 | $18.05 | $204,885.55 |
DisclosureSEC source: 0001104659-23-062374 · tm2316199-5_4seq1.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,748 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.23. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041725 · tm2311410-6_4seq1.xml · derivative · entry 2 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2033-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2024, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041725 · tm2311410-6_4seq1.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,099 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2024 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2027, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:31 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 7,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-000667 · form4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,150 Underlying: Common Stock · 7,317 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 23:20 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-000517 · form4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,833 Underlying: Common Stock · 62,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:15 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-020780 · form4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock and has no expiration date. F3 · shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F3 · derivative.underlying_shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F3 · balance_after: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. Read SEC document |
| May 16, 2022 Filed May 18, 2022 23:03 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 3,436 | $14.59 | $50,131.24 |
DisclosureSEC source: 0001104659-22-062609 · tm2215879-6_4seq1.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,099 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.57 to $14.59. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:17 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 78,750 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001104659-22-042770 · tm2211665-3_4seq1.xml · derivative · entry 2 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires 2032-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:17 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042770 · tm2211665-3_4seq1.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,535 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2023 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2026, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:16 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 20,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-012922 · form4.xml · derivative · entry 2 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,044 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units vested in full on March 31, 2022 and had no expiration date. F2 · derivative.expiration_date: These restricted stock units vested in full on March 31, 2022 and had no expiration date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:16 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 20,044 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-012922 · form4.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 22:25 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 20,044 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-21-000540 · form4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,044 Underlying: Common Stock · 20,044 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units will vest in full on March 31, 2022 and have no expiration date. F2 · derivative.expiration_date: These restricted stock units will vest in full on March 31, 2022 and have no expiration date. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:19 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 69,050 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046731 · tm2112099-12_4seq1.xml · derivative · entry 2 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,050 Underlying: Common Stock · 69,050 shares Expires 2031-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:19 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 46,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046731 · tm2112099-12_4seq1.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,035 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| January 14, 2021 Filed Jan 16, 2021 02:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 14,900 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0001104659-21-004879 · tm213368-1_4seq1.xml · derivative · entry 7 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 14,900 shares Expires 2029-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares underlying this stock option vested on December 9, 2020, the remainder of the shares underlying this stock option will continue to vest in approximately equal monthly installments thereafter until December 9, 2023. Read SEC document |
| January 14, 2021 Filed Jan 16, 2021 02:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 600 | $44.00 | $26,400.00 |
DisclosureSEC source: 0001104659-21-004879 · tm213368-1_4seq1.xml · nonDerivative · entry 5 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · balance_after: The reporting person continues to hold options to acquire 196,350 shares of the Issuer's common stock, 8,750 of which are exercisable as of the date hereof. Read SEC document |
| January 14, 2021 Filed Jan 16, 2021 02:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 14,300 | $44.55 | $637,065.00 |
DisclosureSEC source: 0001104659-21-004879 · tm213368-1_4seq1.xml · nonDerivative · entry 4 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.01 to $45.00. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 14, 2021 Filed Jan 16, 2021 02:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 14,900 | $14.08 | $209,792.00 |
DisclosureSEC source: 0001104659-21-004879 · tm213368-1_4seq1.xml · nonDerivative · entry 3 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2021 Filed Jan 16, 2021 02:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0001104659-21-004879 · tm213368-1_4seq1.xml · derivative · entry 6 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,900 Underlying: Common Stock · 100 shares Expires 2029-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares underlying this stock option vested on December 9, 2020, the remainder of the shares underlying this stock option will continue to vest in approximately equal monthly installments thereafter until December 9, 2023. Read SEC document |
| January 13, 2021 Filed Jan 16, 2021 02:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 100 | $44.19 | $4,419.00 |
DisclosureSEC source: 0001104659-21-004879 · tm213368-1_4seq1.xml · nonDerivative · entry 2 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 13, 2021 Filed Jan 16, 2021 02:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 100 | $14.08 | $1,408.00 |
DisclosureSEC source: 0001104659-21-004879 · tm213368-1_4seq1.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0001104659-20-136479 · tm2038707d1_4.xml · derivative · entry 5 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 25,000 shares Expires 2029-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares underlying this stock option vested on December 9, 2020, the remainder of the shares underlying this stock option will continue to vest in equal monthly installments thereafter until December 9, 2023. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 389 | $42.09 | $16,373.01 |
DisclosureSEC source: 0001104659-20-136479 · tm2038707d1_4.xml · nonDerivative · entry 4 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.01 to $42.15. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F5 · balance_after: The reporting person continues to hold options to acquire 211,350 shares of the Issuer's common stock, 20,000 of which are exercisable as of the date hereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.